share_log

中國生物製藥：二零二三年年報

SINO BIOPHARM: 2023 ANNUAL REPORT

Hong Kong Stock Exchange ·  Apr 29 04:42
Summary by Moomoo AI
信諾生物製藥有限公司已發布截至2023年12月31日的年度報告。報告顯示，該公司在腫瘤、肝病、呼吸系統疾病及骨科/疼痛管理等領域取得顯著進展，並從仿製藥轉型為創新藥物研發。信諾生物製藥的主要創新產品包括治療癌症的安羅替尼膠囊和帕舒瑞單抗注射液，以及用於呼吸病症的布地奈德吸入懸液等。2023財年，公司實現收入261億人民幣，歸屬於公司擁有者的淨利潤為23.3億人民幣。信諾生物製藥在臨床開發階段擁有43個腫瘤候選藥物，並預計在未來幾年獲得新的藥品批准。該公司積極進行國際合作，旨在通過創新產品攻佔國際市場，儘管面臨集中採購的價格壓力，但通過積極的管理措施實現了顯著的銷售增長。此外，信諾生物製藥在呼吸領域的研發管線包括8個處於臨床及以上開發階段的創新候選藥物，預計在未來三年（2024-2026年）獲得新產品批准。2023年，公司在「中國50強創新藥企」和「中國藥業百強競爭力榜」等多項排名中獲得認可。
信諾生物製藥有限公司已發布截至2023年12月31日的年度報告。報告顯示，該公司在腫瘤、肝病、呼吸系統疾病及骨科/疼痛管理等領域取得顯著進展，並從仿製藥轉型為創新藥物研發。信諾生物製藥的主要創新產品包括治療癌症的安羅替尼膠囊和帕舒瑞單抗注射液，以及用於呼吸病症的布地奈德吸入懸液等。2023財年，公司實現收入261億人民幣，歸屬於公司擁有者的淨利潤為23.3億人民幣。信諾生物製藥在臨床開發階段擁有43個腫瘤候選藥物，並預計在未來幾年獲得新的藥品批准。該公司積極進行國際合作，旨在通過創新產品攻佔國際市場，儘管面臨集中採購的價格壓力，但通過積極的管理措施實現了顯著的銷售增長。此外，信諾生物製藥在呼吸領域的研發管線包括8個處於臨床及以上開發階段的創新候選藥物，預計在未來三年（2024-2026年）獲得新產品批准。2023年，公司在「中國50強創新藥企」和「中國藥業百強競爭力榜」等多項排名中獲得認可。
Sinno Biopharmaceuticals Limited has published its annual report for the year ended 31 December 2023. The report shows that the company has made significant progress in areas such as oncology, liver disease, respiratory diseases and orthopedic/pain management, transforming from generic pharmaceutical transformation to innovative drug development. Sinno Biopharmaceutics' main innovations include alotinic capsules and pasurilone anti-injection solution for cancer, as well as Budinid inhalation suspension for respiratory diseases, etc. In fiscal 2023, the company achieved a revenue of RMB261 billion and a net profit of RMB23.3 billion attributable to the owners of the company. Cinno Biopharmaceuticals has 43 tumor candidate drugs in clinical development and is expected to receive new drug approval in the coming years. The company actively cooperates internationally with the aim...Show More
Sinno Biopharmaceuticals Limited has published its annual report for the year ended 31 December 2023. The report shows that the company has made significant progress in areas such as oncology, liver disease, respiratory diseases and orthopedic/pain management, transforming from generic pharmaceutical transformation to innovative drug development. Sinno Biopharmaceutics' main innovations include alotinic capsules and pasurilone anti-injection solution for cancer, as well as Budinid inhalation suspension for respiratory diseases, etc. In fiscal 2023, the company achieved a revenue of RMB261 billion and a net profit of RMB23.3 billion attributable to the owners of the company. Cinno Biopharmaceuticals has 43 tumor candidate drugs in clinical development and is expected to receive new drug approval in the coming years. The company actively cooperates internationally with the aim of capturing the international market through innovative products and achieving significant sales growth through positive management measures, despite the price pressure of centralized procurement. In addition, Sino-Biopharmaceuticals in the respiratory field includes 8 innovative candidate drugs in clinical and above development stages, which are expected to receive new product approval in the next three years (2024-2026). In 2023, the company was recognized in several rankings such as “Top 50 Innovative Pharmaceutical Companies in China” and “Top 100 Competitive List of Chinese Pharmaceuticals”.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more